Overview
Ana Fradinho practices practicing medicine in Lisbon, Portugal.
Her clinical expertise encompasses Age-Related Macular Degeneration (ARMD) and Late-Onset Retinal Degeneration.
She is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ana C. Fradinho
Is Ana C. Fradinho a top-rated expert for Age-Related Macular Degeneration (ARMD)?
MediFind is an objective health platform that identifies experts based on real-world data. Ana C. Fradinho is classified as an Experienced expert for Age-Related Macular Degeneration (ARMD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ana C. Fradinho participate in research or clinical trials?
Yes. Ana C. Fradinho has published 8 articles and abstracts on conditions like Age-Related Macular Degeneration (ARMD). You can view a list of Ana C. Fradinho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Age-Related Macular Degeneration (ARMD)Ms. Fradinho isExperienced. Learn about Age-Related Macular Degeneration (ARMD).
- Late-Onset Retinal DegenerationMs. Fradinho isExperienced. Learn about Late-Onset Retinal Degeneration.